Home | All trials

[RDF data]
Trial NCT00408304

Resource URI: http://static.linkedct.org/resource/trials/NCT00408304
PropertyValue
linkedct:brief_title Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
linkedct:condition <http://static.linkedct.org/resource/condition/2733>
linkedct:criteria Inclusion Criteria: - Chronic carriers of hepatitis C who start a course of interferon alpha treatment, and are treated in the liver clinic of Bnai Zion hospital. Exclusion Criteria: - Disagreement to participation in trial. - Diagnosed and active mental illness. - Encephalopathic patients. - Patients with limited ability to understand the questionnaires or the informed consent process.
linkedct:description Omega-3 fatty acids are known as an alternative treatment for different conditions, including mental conditions, such as depression. We assume that combining omega-3 with the treatment by interferon alpha may prevent the development of depression, which is quite a common side effect of the interferon alpha.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age N/A
linkedct:eligibility_minimum_age N/A
linkedct:end_date December 2007
linkedct:enrollment 60 (xsd:int)
linkedct:firstreceived_date December 5, 2006
linkedct:id NCT00408304
rdfs:label Trial NCT00408304
linkedct:lastchanged_date December 5, 2006
linkedct:lead_sponsor_agency Bnai Zion Medical Center
linkedct:location <http://static.linkedct.org/resource/location/73649>
linkedct:nct_id NCT00408304
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
linkedct:org_study_id Schiff1
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/15789>
linkedct:overall_status Recruiting
linkedct:oversight <http://static.linkedct.org/resource/oversight/1459>
foaf:page <http://clinicaltrials.gov/show/NCT00408304>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/21287>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/21751>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/26056>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/103278>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/12193>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/133031>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/32550>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/3642>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/49900>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/78043>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/7879>
linkedct:source Bnai Zion Medical Center
linkedct:start_date December 2006
linkedct:study_design Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
linkedct:study_type Interventional
linkedct:summary The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.
rdf:type linkedct:trials
linkedct:verification_date December 2006